Objectives: In the context of COVID-19, patients with a severe or critical illness may be more
susceptible to developing secondary bacterial infections. This study aims to investigate the …

Background The incidence of bacterial or fungal coinfections in COVID-19 patients is low.
The incidence of nosocomial superinfections is higher, especially related to ICU admission …

Bacterial infections may complicate the course of COVID-19 patients. The rate and
predictors of bacterial infections were examined in patients consecutively admitted with …

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal
antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …

Background Immunosuppressive therapies have become a cornerstone of the management
of severe COVID-19. The impact of these therapies on secondary infections and …

Methods: We conducted a matched retrospective cohort study from two large, acute care
hospitals in Western Connecticut from March 1, to May 31, 2020. We collected variables …

Background: Severe SARS-CoV-2 (COVID) pneumonia is characterized by marked
inflammation. Current guidelines recommend the addition of the tocilizumab to …

Methods A literature search was conducted using the following evidence-based medicine
reviews: Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic …

Background Tocilizumab is an interleukin-6 inhibitor that reduces mortality and the need for
invasive mechanical ventilation, while increasing the possibility of successful hospital …

Hospitalized patients with SARS-CoV-2 infection (COVID-19) often receive antibiotics for
suspected bacterial coinfection. We estimated the incidence of bacterial coinfection and …